Curi RMB Capital LLC Purchases New Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Curi RMB Capital LLC purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 7,901 shares of the company’s stock, valued at approximately $903,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PCVX. Riverview Trust Co purchased a new stake in Vaxcyte in the third quarter valued at $27,000. Fifth Third Bancorp purchased a new stake in Vaxcyte in the second quarter valued at $35,000. Blue Trust Inc. lifted its position in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. J.Safra Asset Management Corp lifted its position in Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after acquiring an additional 526 shares during the last quarter. Finally, Quest Partners LLC purchased a new stake in Vaxcyte in the second quarter valued at $70,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Down 6.3 %

Shares of Vaxcyte stock opened at $86.83 on Friday. Vaxcyte, Inc. has a 52-week low of $48.24 and a 52-week high of $121.06. The company’s 50-day simple moving average is $110.67 and its 200-day simple moving average is $88.46. The firm has a market cap of $10.82 billion, a price-to-earnings ratio of -18.88 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the business earned ($0.91) EPS. Equities research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,479,005.02. This trade represents a 8.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the transaction, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at approximately $37,822,574.24. This trade represents a 3.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 117,464 shares of company stock worth $12,640,276. 3.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

PCVX has been the subject of a number of research reports. Leerink Partners upped their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Jefferies Financial Group upped their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Bank of America upped their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.